AI assistant
LANXESS AG — Interim / Quarterly Report 2021
Nov 4, 2021
259_10-q_2021-11-04_fe46ad3f-76d2-4f29-8afa-69a6e503cd9a.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
QUARTERLY STATEMENT
as of September 30, 2021
LANXESS GROUP KEY DATA
| € million | Q3 2020 | Q3 2021 | Change % | 9M 2020 | 9M 2021 | Change % |
|---|---|---|---|---|---|---|
| Sales | 1,461 | 1,951 | 33.5 | 4,601 | 5,475 | 19.0 |
| Gross profit | 350 | 482 | 37.7 | 1,179 | 1,384 | 17.4 |
| Gross profit margin | 24.0% | 24.7% | 25.6% | 25.3% | ||
| EBITDA pre exceptionals1) | 193 | 278 | 44.0 | 662 | 797 | 20.4 |
| EBITDA margin pre exceptionals1) | 13.2% | 14.2% | 14.4% | 14.6% | ||
| EBITDA1) | 170 | 237 | 39.4 | 587 | 699 | 19.1 |
| EBIT pre exceptionals1) | 76 | 146 | 92.1 | 312 | 428 | 37.2 |
| EBIT1) | 53 | 104 | 96.2 | 218 | 327 | 50.0 |
| EBIT margin1) | 3.6% | 5.3% | 4.7% | 6.0% | ||
| Net income | 26 | 74 | > 100 | 888 | 238 | (73.2) |
| from continuing operations | 25 | 68 | > 100 | 891 | 208 | (76.7) |
| from discontinued operations | 1 | 6 | > 100 | (3) | 30 | > 100 |
| Weighted average number of shares outstanding | 86,346,303 | 86,346,303 | – | 86,668,937 | 86,346,303 | (0.4) |
| Earnings per share (€) | 0.30 | 0.86 | > 100 | 10.25 | 2.76 | (73.1) |
| from continuing operations | 0.29 | 0.79 | > 100 | 10.28 | 2.41 | (76.6) |
| from discontinued operations | 0.01 | 0.07 | > 100 | (0.03) | 0.35 | > 100 |
| Earnings per share from continuing operations adjusted for exceptional items and amortization of intangible assets (€)2) |
0.66 | 1.41 | > 100 | 2.68 | 3.96 | 47.8 |
| Cash flow from operating activities – continuing operations | 167 | 105 | (37.1) | 332 | 128 | (61.4) |
| Depreciation and amortization | 117 | 133 | 13.7 | 369 | 372 | 0.8 |
| Cash outflows for capital expenditures | 102 | 109 | 6.9 | 264 | 271 | 2.7 |
| Total assets | 8,8805) | 9,570 | 7.8 | |||
| Equity (including non-controlling interests) | 2,9995) | 3,602 | 20.1 | |||
| Equity ratio3) | 33.8%5) | 37.6% | ||||
| Provisions for pensions and other post-employment benefits |
1,2055) | 903 | (25.1) | |||
| Net financial liabilities4) | 1,0125) | 2,343 | > 100 | |||
| Employees (as of Sep. 30) | 14,7565)6) | 14,8666) | 0.7 |
1) EBIT: earnings before interest and taxes.
EBIT pre exceptionals: EBIT disregarding exceptional charges and income.
EBIT margin: EBIT in relation to sales.
EBITDA: EBIT before depreciation of property, plant and equipment and amortization of intangible assets, less reversals of impairment charges on property, plant, equipment and intangible assets.
EBITDA pre exceptionals: EBITDA disregarding exceptional charges and income.
EBITDA margin pre exceptionals: EBITDA pre exceptionals in relation to sales.
Please see "Notes on EBIT and EBITDA (Pre Exceptionals)" for details.
2) Earnings per share from continuing operations adjusted for exceptional items and amortization of intangible assets: earnings per share from continuing operations disregarding exceptional charges and income, amortization of intangible assets and attributable tax effects as well as non-recurring earnings effects in the second quarter of 2020 relating to the sale of the 40% interest in Currenta GmbH & Co. OHG. See "Net income/earnings per share/earnings per share from continuing operations adjusted for exceptional items and amortization of intangible assets" for details.
3) Equity ratio: equity in relation to total assets.
4) Net financial liabilities: sum of current and non-current financial liabilities (adjusted for liabilities for accrued interest) less cash, cash equivalents and near-cash assets.
See "Statement of Financial Position and Financial Condition" for details.
5) As of December 31, 2020.
6) There were 14,866 employees in continuing operations as of the reporting date after 14,309 as of December 31, 2020.
CONTENTS
| LANXESS Group Key Data |
|---|
| 1 Quarterly Statement as of September 30, 2021 |
| 1 Reporting Focus and Material Transactions |
| 2 Business Performance |
| 5 Business Development by Region |
| 6 Segment Information |
| 11 Notes on EBIT and EBITDA (Pre Exceptionals) |
| 12 Statement of Financial Position and Financial Condition |
| 13 Outlook |
| 14 Financial Data as of September 30, 2021 |
| 14 Statement of Financial Position LANXESS Group |
| 15 Income Statement LANXESS Group |
| 15 Statement of Comprehensive Income LANXESS Group |
| 16 Statement of Changes in Equity LANXESS Group |
| 17 Statement of Cash Flows LANXESS Group |
| 18 Business Unit Key Data |
Financial Calendar/Contacts/Masthead
QUARTERLY STATEMENT AS OF SEPTEMBER 30, 2021
- › Acquisition of Emerald Kalama Chemical completed on August 3, 2021
- › Agreement signed to acquire IFF Microbial Control
- › Sales and earnings in all segments up year-on-year in the third quarter
- › EBITDA pre exceptionals up 44% year-on-year to €278 million
- › Strong business performance in the Specialty Additives and Engineering Materials segments
- › Increased raw material costs passed on to customers
- › High energy and freight costs counteract further earnings increase
- › Earnings per share from continuing operations adjusted for exceptional items and amortization of intangible assets of €1.41 in the third quarter against €0.66 in the previous year
- › Guidance for fiscal year 2021 specified: EBITDA pre exceptionals at the lower end of the range of €1,000 million to €1,050 million
REPORTING FOCUS AND MATERIAL TRANSACTIONS
As of January 1, 2021, the business with antioxidants and reaction accelerators was organizationally reassigned from the Advanced Intermediates segment's Advanced Industrial Intermediates business unit to the Specialty Additives segment's Rhein Chemie business unit. The previous year's figures have been restated accordingly. At the same time, the business with colorants and colorant additives was organizationally transferred within the Specialty Additives segment from the Rhein Chemie business unit to the Polymer Additives business unit.
We decided in 2019 to divest all operations of the Leather business unit, comprising chrome chemicals, the chrome ore mine and organic leather chemicals. In connection with this, LANXESS sold its chrome chemicals business on January 10, 2020. The organic leather chemicals business was disposed of on June 1 of the current fiscal year. The sale of the chrome ore mine was completed on September 15, 2021. The Leather business unit had been recognized as discontinued operations since December 2019.
As of January 1, 2021, LANXESS completed the sale of the reverse osmosis membranes business from the Liquid Purification Technologies business unit to SUEZ S.A., Paris, France. LANXESS has thus repositioned its water treatment technology business in order to focus on the ion exchange resins business in the future.
On March 1, 2021, LANXESS completed the acquisition of the French company INTACE SAS, Paris, France. This manufacturer of special fungicides for the packaging and paper industry will enhance LANXESS's position as one of the world's leading producers of biocides and antimicrobial active ingredients. The business was integrated into the Material Protection Products business unit of the Consumer Protection segment. The company generated sales in the mid-single-digit millions in euros in the previous year.
On April 1, 2021, LANXESS completed the acquisition of the French Theseo Group, a leading manufacturer of disinfection and hygiene solutions in Europe and Latin America headquartered in Laval, France. With this acquisition, LANXESS has expanded its portfolio with products for pest control, animal nutrition and animal health and now offers and extensive range of disinfection and hygiene solutions. The business with around 100 employees at its sites in Laval, France; Wietmarschen, Germany; Hull, Great Britain; and Descalvado, Brazil, was integrated into the Material Protection Products business unit of the Consumer Protection segment. In 2020, the acquired group generated sales in the lower double-digit millions in euros.
On August 3, 2021, LANXESS acquired 100% of the shares in Emerald Kalama Chemical from U.S. private equity firm American Securities LLC. As one of the world's leading manufacturers of specialty chemicals, the U.S. company generated around three-quarters of its sales from consumer goods. These include preservatives for use in food, household products and cosmetics, flavors and fragrances as well as preservative products for animal nutrition and animal health. LANXESS brought this business into the newly founded Flavors & Fragrances business unit, which is part of the Consumer Protection segment. In addition, the product portfolio is expanded by specialty chemicals for industrial applications, such as for the plastics and adhesives industries. These products were integrated into the Polymer Additives business unit of the Specialty Additives segment. As of October 1, 2021, the benzyl products of the Advanced Industrial Intermediates business unit were also added to the new Flavors & Fragrances business unit. The acquisition of Emerald Kalama Chemical is a targeted enhancement of LANXESS's position in the global business with antimicrobial active ingredients and preservatives, especially for consumer protection products and animal health. The enterprise value was US\$1.075 billion. LANXESS financed the purchase price with existing liquidity. LANXESS took on around 470 employees worldwide as well as production sites in Kalama, U.S.; Rotterdam, Netherlands; and Widnes, Great Britain. In 2020, the acquired company generated sales of around US\$425 million and EBITDA pre exceptionals of roughly US\$90 million.
On August 23, 2021, LANXESS signed an agreement with the U.S. corporation International Flavors & Fragrances Inc. (IFF) to acquire its Microbial Control business. IFF Microbial Control is one of the leading providers of antimicrobial active ingredients and formulations for material protection, preservatives and disinfectants. The products are used in numerous applications, especially in personal care and household products, in industrial water treatment, and in paints and coatings. IFF Microbial Control has around 270 employees and runs two production plants of its own in St. Charles, Louisiana, and Institute, West Virginia, U.S. The business also has a large network of partners including active ingredient manufacturers and formulators. Once the acquisition is completed, the business is to be integrated into the Material Protection Products business unit of the Consumer Protection segment. The enterprise value of the IFF Microbial Control business amounts to around US\$1.3 billion. The transaction is expected to be completed in the second quarter of the next fiscal year.
Due to the recent acquisitions, the Board of Management of LANXESS AG has decided to re-prioritize its capital allocation and not to continue the stock repurchase program, which has been suspended since the coronavirus crisis. 1,101,549 shares worth €37 million were acquired in March and April of the previous year, and were canceled on September 22, 2021.
BUSINESS PERFORMANCE
Sales
The LANXESS Group's sales of €1,951 million were €490 million, or 34%, higher than in the previous year, which was significantly affected by the coronavirus pandemic. The sales development was influenced in particular by significantly higher selling prices driven by raw material prices and the continued revival in demand. Overall, higher selling prices increased sales by 18.7% and higher volumes pushed up sales by 9.9%. The contributions from the U.S. company Emerald Kalama Chemical acquired at the beginning of August 2021, from the French company INTACE SAS acquired at the beginning of March 2021, and from the French Theseo Group acquired on April 1, 2021, also had a positive effect. The sale of the reverse osmosis membranes business from the Liquid Purification Technologies business unit had a slightly negative effect. Overall, the portfolio effect had a positive influence on sales at Group level of 5.1%. Shifts in exchange rates led to a slight sales decline.
Effects on Sales
| % | Q3 2021 | 9M 2021 |
|---|---|---|
| Price | 18.7 | 8.3 |
| Volume | 9.9 | 12.0 |
| Currency | (0.2) | (3.0) |
| Portfolio | 5.1 | 1.7 |
| 33.5 | 19.0 |
EBITDA and operating result (EBIT)
EBITDA Pre Exceptionals by Segment
| € million | Q3 2020 | Q3 2021 | Change % | 9M 2020 | 9M 2021 | Change % |
|---|---|---|---|---|---|---|
| Advanced Intermediates | 71 | 84 | 18.3 | 256 | 257 | 0.4 |
| Specialty Additives | 59 | 102 | 72.9 | 210 | 265 | 26.2 |
| Consumer Protection | 59 | 60 | 1.7 | 194 | 194 | 0.0 |
| Engineering Materials | 33 | 62 | 87.9 | 110 | 189 | 71.8 |
| Reconciliation | (29) | (30) | (3.4) | (108) | (108) | 0.0 |
| 193 | 278 | 44.0 | 662 | 797 | 20.4 | |
| Prior-year figures restated |
In an economic environment that continues to recover, the operating result before depreciation, amortization, write-downs and reversals (EBITDA) pre exceptionals amounted to €278 million in the third quarter of 2021, considerably higher than the prioryear quarter. In the previous year, EBITDA pre exceptionals amounted to €193 million. The effect of continued good demand particularly benefited the Specialty Additives and Engineering Materials segments. All segments generally saw positive business development, but this was weakened by a sharp rise in energy and freight costs. The significantly increased raw material prices were passed on to the market via a successful increase of selling prices. The contribution of the U.S. company Emerald Kalama Chemical, acquired in August, also had a positive effect. The other businesses acquired over the year and the sale of the reverse osmosis membranes business from the Liquid Purification Technologies business unit also had a positive effect on earnings. The change in exchange rates mostly had a slightly negative effect in the segments. Please see the table below and "Segment Information" for details on the individual segments.
Primarily due to higher freight costs and volume effects, selling expenses rose by 31.0% to €241 million. Research and development costs amounted to €31 million, compared to €26 million in the prior-year period, while general administration expenses amounted to €70 million, compared to €57 million in the prior-year period, partly due to portfolio effects. The Group EBITDA margin pre exceptionals came in at 14.2%, against 13.2% in the prior-year quarter.
Depreciation, amortization and write-downs rose by €16 million, or 12.8%, compared with the figure for the prior-year quarter
Reconciliation of EBITDA Pre Exceptionals to EBIT
| € million | Q3 2020 | Q3 2021 | Change % | 9M 2020 | 9M 2021 | Change % |
|---|---|---|---|---|---|---|
| EBITDA pre exceptionals | 193 | 278 | 44.0 | 662 | 797 | 20.4 |
| Depreciation and amortization | (117) | (133) | (13.7) | (369) | (372) | (0.8) |
| Exceptional items in EBITDA | (23) | (41) | (78.3) | (75) | (98) | (30.7) |
| Operating result (EBIT) | 53 | 104 | 96.2 | 218 | 327 | 50.0 |
to €133 million, primarily due to the acquisition of Emerald Kalama Chemical in August. The depreciation, amortization and write-downs include write-downs of €4 million. Net negative exceptional items of €42 million included in other operating income and expenses, which impacted EBITDA by a total of €41 million and resulted primarily from expenses in connection with the M&A and integration activities as part of the acquisition of Emerald Kalama Chemical and with digitalization projects. In the prior-year quarter, the operating result included negative exceptional items totaling €23 million.
Financial result
The financial result for the third quarter of 2021 was minus €10 million, compared with minus €19 million for the prior-year period. The improvement in earnings resulted primarily from an increase in the fair value of warrants to acquire shares of the company Standard Lithium Ltd., Canada. The net interest result was minus €14 million, compared with minus €11 million in the prior-year quarter. The other financial result improved from minus €8 million in the prior-year quarter to €4 million.
Income before income taxes
In the third quarter of 2021, income before income taxes came to €94 million, against €34 million for the prior-year period. The effective tax rate was 27.7%, compared with 26.5% for the prior-year quarter.
Net income/earnings per share/earnings per share from continuing operations adjusted for exceptional items and amortization of intangible assets
Net income for the reporting period amounted to €74 million, of which €68 million was attributable to continuing operations. In the prior-year quarter, €25 million of the net income of €26 million was allocable to continuing operations. The increase in earnings resulted primarily from the good development of the operating businesses and the contribution from the acquired business of Emerald Kalama Chemical. Net income of €6 million was attributable to discontinued operations in the third quarter, which largely resulted from the gain on disposal from the sale of the chrome ore mine completed on September 15, 2021. In the prior-year quarter, net income of minus €1 million was attributable to discontinued operations. No earnings were attributable to non-controlling interests in the third quarter of 2021. In the prior-year period, negative earnings from continuing operations of €1 million were attributable to non-controlling interests.
Earnings per share are calculated by dividing net income by the weighted average number of LANXESS shares outstanding during the reporting period. Earnings per share amounted to €0.86, which was higher than the prior-year figure of €0.30. Earnings per share from continuing operations were €0.79 against €0.29 in the prior-year quarter.
Earnings per Share
| Q3 2020 | Q3 2021 | 9M 2020 | 9M 2021 | |
|---|---|---|---|---|
| Net income (€ million) | 26 | 74 | 888 | 238 |
| from continuing operations (€ million) | 25 | 68 | 891 | 208 |
| from discontinued operations (€ million) | 1 | 6 | (3) | 30 |
| Weighted average number of shares outstanding | 86,346,303 | 86,346,303 | 86,668,937 | 86,346,303 |
| Earnings per share (€) | 0.30 | 0.86 | 10.25 | 2.76 |
| from continuing operations (€) | 0.29 | 0.79 | 10.28 | 2.41 |
| from discontinued operations (€) | 0.01 | 0.07 | (0.03) | 0.35 |
We also calculate earnings per share from continuing operations pre exceptionals and amortization of intangible assets, which are not defined by International Financial Reporting Standards. This value was calculated from the earnings per share from continuing operations adjusted for exceptional items, amortization of intangible assets and attributable tax effects. Earnings per share from continuing operations pre exceptionals and amortization of intangible assets were €1.41 in the third quarter of 2021 against €0.66 in the corresponding prior-year period.
Reconciliation to Earnings per Share from Continuing Operations Adjusted for Exceptional Items and Amortization of Intangible Assets
| € million | Q3 2020 | Q3 2021 | 9M 2020 | 9M 2021 |
|---|---|---|---|---|
| Net income from continuing operations | 25 | 68 | 891 | 208 |
| Exceptional items1) | 23 | 42 | 94 | 101 |
| Amortization of intangible assets/reversals of impairment charges1) | 21 | 29 | 65 | 79 |
| Income in connection with the sale of Currenta GmbH & Co. OHG1) | 0 | 0 | (890) | 0 |
| Income taxes1) | (12) | (17) | 72 | (46) |
| Net income from continuing operations adjusted for exceptional items and amortization | ||||
| of intangible assets | 57 | 122 | 232 | 342 |
| Weighted average number of shares outstanding | 86,346,303 | 86,346,303 | 86,668,937 | 86,346,303 |
| Earnings per share from continuing operations adjusted for exceptional items and | ||||
| amortization of intangible assets (€) | 0.66 | 1.41 | 2.68 | 3.96 |
1) Excluding items attributable to non-controlling interests
BUSINESS DEVELOPMENT BY REGION
Group sales in the third quarter of 2021 amounted to €1,951 million, up 34% on the previous year's figure of €1,461 million. All regions saw positive business development.
Sales by Market
| Q3 2020 | Q3 2021 | 9M 2020 | 9M 2021 | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| € million | % | € million | % | % € million | % | € million | % | % | ||
| EMEA (excl. Germany) | 430 | 29.4 | 587 | 30.1 | 36.5 | 1,401 | 30.4 | 1,716 | 31.4 | 22.5 |
| Germany | 265 | 18.1 | 343 | 17.6 | 29.4 | 849 | 18.5 | 1,007 | 18.4 | 18.6 |
| North America | 359 | 24.6 | 454 | 23.3 | 26.5 | 1,097 | 23.8 | 1,223 | 22.3 | 11.5 |
| Latin America | 74 | 5.1 | 118 | 6.0 | 59.5 | 220 | 4.8 | 303 | 5.5 | 37.7 |
| Asia-Pacific | 333 | 22.8 | 449 | 23.0 | 34.8 | 1,034 | 22.5 | 1,226 | 22.4 | 18.6 |
| 1,461 | 100.0 | 1,951 | 100.0 | 33.5 | 4,601 | 100.0 | 5,475 | 100.0 | 19.0 |
SEGMENT INFORMATION
Advanced Intermediates
| Q3 2020 | Q3 2021 | Change | 9M 2020 | 9M 2021 | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| € million | Margin % | € million | Margin % | % | € million | Margin % | € million | Margin % | % | ||
| Sales | 414 | 533 | 28.7 | 1,327 | 1,527 | 15.1 | |||||
| EBITDA pre exceptionals | 71 | 17.1 | 84 | 15.8 | 18.3 | 256 | 19.3 | 257 | 16.8 | 0.4 | |
| EBITDA | 71 | 17.1 | 84 | 15.8 | 18.3 | 254 | 19.1 | 257 | 16.8 | 1.2 | |
| Operating result (EBIT) pre exceptionals | 43 | 10.4 | 53 | 9.9 | 23.3 | 171 | 12.9 | 165 | 10.8 | (3.5) | |
| Operating result (EBIT) | 43 | 10.4 | 53 | 9.9 | 23.3 | 169 | 12.7 | 165 | 10.8 | (2.4) | |
| Cash outflows for capital expenditures | 28 | 31 | 10.7 | 79 | 83 | 5.1 | |||||
| Depreciation and amortization | 28 | 31 | 10.7 | 85 | 92 | 8.2 | |||||
| Employees as of Sep. 30 (previous year: as of Dec. 31) | 3,340 | 3,363 | 0.7 | 3,340 | 3,363 | 0.7 | |||||
| Prior-year figures restated |
Our Advanced Intermediates segment recorded sales of €533 million in the third quarter, up 28.7%, or €119 million, on the figure for the prior-year period. The sales development was particularly influenced by the sharp rise in selling prices in both business units, which were above the previous year's level as much higher raw material prices were passed on. Overall, there was a positive price effect on sales of 22.7% at segment level. At segment level, the continued good demand in both business units also resulted in volume-driven sales growth of 6.3%. Shifts in exchange rates had a slightly negative effect on the segment. Sales in all regions were above the level of the prior-year quarter.
EBITDA pre exceptionals in the Advanced Intermediates segment increased by 18.3% to €84 million, compared with the previous year's figure of €71 million. The continued significant rise in raw material prices was passed on to the market in the third quarter. The predominantly higher sales volumes in the segment also led to an improvement in earnings. In contrast, earnings were burdened by higher energy and freight costs. Shifts in exchange rates also reduced earnings in both business units. The EBITDA margin pre exceptionals was 15.8%, against 17.1% in the prior-year quarter.
Specialty Additives
| Q3 2020 | Q3 2021 | Change | 9M 2020 | 9M 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| € million | Margin % | € million | Margin % | % | € million | Margin % | € million | Margin % | % | |
| Sales | 466 | 605 | 29.8 | 1,482 | 1,690 | 14.0 | ||||
| EBITDA pre exceptionals | 59 | 12.7 | 102 | 16.9 | 72.9 | 210 | 14.2 | 265 | 15.7 | 26.2 |
| EBITDA | 54 | 11.6 | 98 | 16.2 | 81.5 | 198 | 13.4 | 256 | 15.1 | 29.3 |
| Operating result (EBIT) pre exceptionals | 14 | 3.0 | 58 | 9.6 | > 100 | 77 | 5.2 | 139 | 8.2 | 80.5 |
| Operating result (EBIT) | 9 | 1.9 | 54 | 8.9 | > 100 | 65 | 4.4 | 129 | 7.6 | 98.5 |
| Cash outflows for capital expenditures | 29 | 30 | 3.4 | 69 | 70 | 1.4 | ||||
| Depreciation and amortization | 45 | 44 | (2.2) | 133 | 127 | (4.5) | ||||
| Employees as of Sep. 30 (previous year: as of Dec. 31) | 3,083 | 3,048 | (1.1) | 3,083 | 3,048 | (1.1) | ||||
| Prior-year figures restated |
Sales in our Specialty Additives segment rose by 29.8% in the third quarter of 2021 to €605 million. Higher selling prices due to passing on the sharp rise in raw material prices and generally improved demand resulted in positive sales development in all business units of the segment. Higher selling prices increased sales by 14.8% at segment level. Increased volumes raised sales by 13.1%. In addition, a positive sales contribution of 2.8% was made by the specialty chemicals business, integrated into the Polymer Additives business unit, of the U.S. company Emerald Kalama Chemical, which was acquired at the beginning of August. By contrast, the change in exchange rates decreased sales slightly. Sales in all regions were above the level of the prior-year quarter.
EBITDA pre exceptionals in the Specialty Additives segment significantly increased by €43 million, or 72.9%, to €102 million. The strong earnings development resulted primarily from higher selling prices due to the rise in raw material prices since the start of the year as well as increasing demand from the construction, oil, gas, and aviation industries and the associated rise in sales volumes in all business units of the segment. In contrast, earnings were burdened by increased energy and freight costs. Earnings were likewise reduced by adverse exchange rate effects. The contribution from Emerald Kalama Chemical's specialty chemicals business, acquired at the beginning of August, had a slightly positive effect on earnings. The EBITDA margin pre exceptionals was 16.9%, against 12.7% in the prior-year period.
The segment recorded negative exceptional items of €4 million in the third quarter, which impacted EBITDA and primarily related to the strategic realignment. In the previous year, negative exceptional items of €5 million were incurred in the operating result. Please see "Notes on EBIT and EBITDA (Pre Exceptionals)" for details.
Consumer Protection
| Q3 2020 | Q3 2021 Change |
9M 2020 | 9M 2021 | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| € million | Margin % | € million | Margin % | % | € million | Margin % | € million | Margin % | % | |
| Sales | 278 | 353 | 27.0 | 858 | 957 | 11.5 | ||||
| EBITDA pre exceptionals | 59 | 21.2 | 60 | 17.0 | 1.7 | 194 | 22.6 | 194 | 20.3 | 0.0 |
| EBITDA | 59 | 21.2 | 54 | 15.3 | (8.5) | 191 | 22.3 | 188 | 19.6 | (1.6) |
| Operating result (EBIT) pre exceptionals | 40 | 14.4 | 33 | 9.3 | (17.5) | 134 | 15.6 | 129 | 13.5 | (3.7) |
| Operating result (EBIT) | 40 | 14.4 | 27 | 7.6 | (32.5) | 113 | 13.2 | 123 | 12.9 | 8.8 |
| Cash outflows for capital expenditures | 15 | 22 | 46.7 | 37 | 48 | 29.7 | ||||
| Depreciation and amortization | 19 | 27 | 42.1 | 78 | 65 | (16.7) | ||||
| Employees as of Sep. 30 (previous year: as of Dec. 31) | 2,439 | 2,932 | 20.2 | 2,439 | 2,932 | 20.2 |
In our Consumer Protection segment, sales amounted to €353 million in the reporting quarter of 2021, up 27.0% from the prior-year level. This was particularly attributable to the sales of the new Flavors & Fragrances business unit, which includes the business with specialty chemicals for the consumer goods sector of U.S. company Emerald Kalama Chemical, which was acquired at the beginning of August. In addition, the Material Protection Products business unit posted higher sales due to the integration of the French company INTACE SAS acquired at the beginning of March 2021 and the French Theseo Group acquired on April 1, 2021, whereas the Liquid Purification Technologies business unit saw a decline in sales as a result of the sale of the reverse osmosis membranes business. Overall, there was a positive portfolio effect of 21.9% at segment level. All business units achieved higher selling prices, which pushed up sales by 3.3%. The Material Protection Products business unit also achieved slightly higher sales volumes. By contrast, the Saltigo business unit saw lower sales volumes, which was particularly attributable to an unscheduled production shutdown. At segment level, higher volumes resulted in sales growth of 1.1%. Shifts in exchange rates had a largely positive effect in the business units and generally had a slightly positive effect on sales at segment level. Sales in all regions were above the level of the prior-year quarter.
EBITDA pre exceptionals in the Consumer Protection segment increased by €1 million, or 1.7%, compared with the prior-year level of €59 million. A positive earnings contribution resulted in particular from the integration of the business with specialty chemicals for the consumer goods sector of U.S. company Emerald Kalama Chemical, which was acquired at the beginning of August, into the new Flavors & Fragrances business unit. The sale of the reverse osmosis membranes business from the Liquid Purification Technologies business unit, the contribution of the French company INTACE SAS acquired at the beginning of March 2021 and the integration of the French Theseo Group acquired on April 1 also had a positive effect on earnings. Higher sales volumes in the Material Protection Products business unit and increased selling prices in all of the segment's business units had a positive effect on earnings. Increased energy costs, a generally difficult logistics situation, an unscheduled production shutdown, and the change in exchange rates had a negative impact on earnings development. The EBITDA margin pre exceptionals was 17.0%, against 21.2% in the prior-year period.
The segment recorded negative exceptional items of €6 million in the third quarter, which impacted EBITDA and primarily related to the strategic realignment of the specialty chemicals business and the associated integration of Emerald Kalama Chemical. No exceptional items were attributable to the segment result in the prior-year quarter. Please see "Notes on EBIT and EBITDA (Pre Exceptionals)" for details.
Engineering Materials
| Q3 2020 | Q3 2021 | 9M 2020 | 9M 2021 | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| € million | Margin % | € million | Margin % | % | € million | Margin % | € million | Margin % | % | |
| Sales | 285 | 436 | 53.0 | 876 | 1,237 | 41.2 | ||||
| EBITDA pre exceptionals | 33 | 11.6 | 62 | 14.2 | 87.9 | 110 | 12.6 | 189 | 15.3 | 71.8 |
| EBITDA | 32 | 11.2 | 62 | 14.2 | 93.8 | 109 | 12.4 | 188 | 15.2 | 72.5 |
| Operating result (EBIT) pre exceptionals | 16 | 5.6 | 44 | 10.1 | > 100 | 60 | 6.8 | 136 | 11.0 | > 100 |
| Operating result (EBIT) | 15 | 5.3 | 44 | 10.1 | > 100 | 59 | 6.7 | 135 | 10.9 | > 100 |
| Cash outflows for capital expenditures | 19 | 12 | (36.8) | 39 | 34 | (12.8) | ||||
| Depreciation and amortization | 17 | 18 | 5.9 | 50 | 53 | 6.0 | ||||
| Employees as of Sep. 30 (previous year: as of Dec. 31) | 2,191 | 2,250 | 2.7 | 2,191 | 2,250 | 2.7 |
In the third quarter of 2021, sales in our Engineering Materials segment increased significantly by 53.0% compared with the previous year's figure, which was influenced by the effects of the coronavirus pandemic, to €436 million. Both selling prices and sales volumes of the two business units exceeded the previous year. 35.4% of the significant sales increase resulted from increased prices and 17.2% from higher volumes. Particularly in the High Performance Materials business unit, this was driven by continued good demand from the automotive industry. The change in exchange rates had a slightly positive influence on both business units. Sales in all regions were above the level of the prior-year quarter.
EBITDA pre exceptionals in the Engineering Materials segment increased by €29 million, or 87.9%, to €62 million. The earnings development resulted primarily from the good demand from the automotive industry and the associated rise in sales volumes in the High Performance Materials business unit. Sharply increased procurement prices for raw materials were passed on to the market. Higher energy and freight costs had a negative effect on earnings. Shifts in exchange rates had no material effect. The EBITDA margin pre exceptionals of 14.2% was above the figure of 11.6% posted in the prior-year quarter.
No exceptional items were attributable to the segment result in the third quarter. In the previous year, negative exceptional items of €1 million were incurred in the operating result. Please see "Notes on EBIT and EBITDA (Pre Exceptionals)" for details.
Reconciliation
| € million | Q3 2020 | Q3 2021 | Change % | 9M 2020 | 9M 2021 | Change % |
|---|---|---|---|---|---|---|
| Sales | 18 | 24 | 33.3 | 58 | 64 | 10.3 |
| EBITDA pre exceptionals | (29) | (30) | (3.4) | (108) | (108) | 0.0 |
| EBITDA | (46) | (61) | (32.6) | (165) | (190) | (15.2) |
| Operating result (EBIT) pre exceptionals | (37) | (42) | (13.5) | (130) | (141) | (8.5) |
| Operating result (EBIT) | (54) | (74) | (37.0) | (188) | (225) | (19.7) |
| Cash outflows for capital expenditures | 11 | 14 | 27.3 | 40 | 36 | (10.0) |
| Depreciation and amortization | 8 | 13 | 62.5 | 23 | 35 | 52.2 |
| Employees as of Sep. 30 (previous year: as of Dec. 31) | 3,256 | 3,273 | 0.5 | 3,256 | 3,273 | 0.5 |
EBITDA pre exceptionals for the reconciliation came to minus €30 million in the third quarter, compared with minus €29 million in the corresponding prior-year period. In the third quarter, negative exceptional items of €32 million were incurred, €31 million of which impacted EBITDA. The exceptional items resulted primarily from expenses in connection with digitalization projects and M&A activities. In the prior-year period, there were negative exceptional items of €17 million, which fully impacted EBITDA. Please see "Notes on EBIT and EBITDA (Pre Exceptionals)" for details.
NOTES ON EBIT AND EBITDA (PRE EXCEPTIONALS)
In order to better assess our operational business and to steer earning power at Group level and for the individual segments, we additionally calculate the earnings indicators EBITDA, and EBITDA and EBIT pre exceptionals, none of which are defined by International Financial Reporting Standards. These indicators are viewed as supplementary to the data prepared according to IFRS; they are not a substitute.
EBITDA is calculated from earnings (EBIT) by adding back depreciation and impairments of property, plant and equipment as well as amortization and impairments of intangible assets and subtracting reversals of impairment charges on property, plant, equipment and intangible assets.
EBIT pre exceptionals and EBITDA pre exceptionals are EBIT and EBITDA before exceptional items. The latter are effects that, by nature or extent, have a significant impact on the earnings position, but for which inclusion in the evaluation
Reconciliation to EBIT/EBITDA
| EBIT | EBIT | EBITDA | EBITDA | EBIT | EBIT | EBITDA | EBITDA | |
|---|---|---|---|---|---|---|---|---|
| € million | Q3 2020 | Q3 2021 | Q3 2020 | Q3 2021 | 9M 2020 | 9M 2021 | 9M 2020 | 9M 2021 |
| EBIT/EBITDA pre exceptionals | 76 | 146 | 193 | 278 | 312 | 428 | 662 | 797 |
| Advanced Intermediates | 0 | 0 | 0 | 0 | (2) | 0 | (2) | 0 |
| Strategic realignment | – | – | – | – | (2) | – | (2) | – |
| Specialty Additives | (5) | (4) | (5) | (4) | (12) | (10) | (12) | (9) |
| Strategic realignment | (5) | (4) | (5) | (4) | (12) | (10) | (12) | (9) |
| Consumer Protection | 0 | (6) | 0 | (6) | (21) | (6) | (3) | (6) |
| Strategic realignment | – | (6) | – | (6) | (20) | (6) | (2) | (6) |
| Other | – | – | – | – | (1) | – | (1) | – |
| Engineering Materials | (1) | 0 | (1) | 0 | (1) | (1) | (1) | (1) |
| Strategic realignment | (1) | 0 | (1) | 0 | (1) | (1) | (1) | (1) |
| Reconciliation | (17) | (32) | (17) | (31) | (58) | (84) | (57) | (82) |
| Strategic realignment | (2) | – | (2) | – | (4) | – | (4) | – |
| Adjustment of the production network | – | – | – | – | (10) | – | (10) | – |
| Strategic IT projects (SAP S/4HANA and other IT | ||||||||
| applications) | (5) | (5) | (5) | (5) | (18) | (18) | (18) | (18) |
| Digitalization, M&A expenses and other | (10) | (27) | (10) | (26) | (26) | (66) | (25) | (64) |
| Total exceptional items | (23) | (42) | (23) | (41) | (94) | (101) | (75) | (98) |
| EBIT/EBITDA | 53 | 104 | 170 | 237 | 218 | 327 | 587 | 699 |
of business performance over several reporting periods does not seem to be appropriate. Exceptional items may include write-downs, reversals of impairment charges or the proceeds from the disposal of assets, certain expenses for strategic projects in the fields of IT and digitalization, restructuring expenses and income from the reversal of provisions established in this connection, and reductions in earnings resulting from portfolio adjustments or purchase price allocations. Grants and subsidies from third parties for the acquisition and construction of property, plant and equipment are accounted for as deferred income using the gross method. In this respect, no adjustments other than for gross depreciation and amortization are made when calculating EBITDA pre exceptionals.
Every operational decision or achievement is judged in the short and long term by its sustainable impact on EBITDA pre exceptionals. As part of the annual budget (target) planning process, targets are set for this benchmark of our company's success, which are then taken into account in determining variable income components for the Board of Management, senior executives and the rest of the workforce.
The earnings margins are calculated from the ratios of the respective earnings indicators to sales. For example, the EBITDA margin (pre exceptionals) is calculated as the ratio of EBITDA (pre exceptionals) to sales and serves as an indicator of relative earning power at Group level and for the individual segments.
STATEMENT OF FINANCIAL POSITION AND FINANCIAL CONDITION
Structure of the statement of financial position
As of September 30, 2021, the LANXESS Group's total assets stood at €9,570 million, up €690 million, or 7.8%, from €8,880 million on December 31, 2020. This development was attributable in particular to the acquisition of Emerald Kalama Chemical. Equity increased by €603 million compared with December 31, 2020, to €3,602 million. The equity ratio at the end of the third quarter was 37.6%, after 33.8% as of December 31, 2020.
Financial position
Changes in the statement of cash flows
The following comments on the statement of cash flows relate to LANXESS's continuing operations.
In the first nine months of 2021, there was a net cash inflow of €128 million from operating activities, against €332 million in the prior-year period. Income before income taxes declined from €1,050 million to €287 million. This was adjusted for the financial result, which in the previous year primarily resulted from the sale of the 40% interest in Currenta GmbH Co. OHG, Leverkusen, Germany. In the reporting period, non-cash depreciation, amortization and write-downs amounted to €372 million, against €369 million in the previous year. The change in net working capital resulted in a net cash outflow of €511 million, compared with €98 million in the prior-year period. The outflow resulted in particular from the increase in inventories due to the sharp rise in raw material prices. Income taxes paid resulted in a net cash outflow of €40 million, against €135 million in the previous year.
There was a €56 million net cash inflow from investing activities in the first nine months of 2021, compared with a €61 million net cash outflow in the same period a year ago. The net cash inflow of the reporting period resulted primarily from cash inflows from financial assets due to the maturity of short-term money market investments. The cash outflow for the successfully completed acquisitions, particularly of Emerald Kalama Chemical, had the opposite effect. Cash outflows for purchases of intangible assets and property, plant and equipment resulted in a net cash outflow of €271 million, compared with €264 million in the first nine months of the previous year.
Net cash used for financing activities came to €159 million in the reporting period, compared with €206 million in the first nine months of 2020. The cash outflow in the reporting period was due in particular to dividend payments of €86 million to LANXESS shareholders as well as interest paid and other financial disbursements. In the previous year, there were also cash outflows for the acquisition of own shares. Repayments
of borrowings and proceeds from borrowings reflected the early repayment of the Eurobond that would have matured in October 2021 and the borrowing of a six-year Eurobond, both with a volume of €500 million.
Financing and liquidity
Net financial liabilities totaled €2,343 million as of September 30, 2021, compared with €1,012 million as of December 31, 2020. The increase in net financial liabilities resulted primarily from the payment of the purchase price for the acquisition of Emerald Kalama Chemical. The purchase price was financed with existing liquidity.
In mid-September, LANXESS successfully issued a euro benchmark bond of €500 million with a term of six years and a coupon of 0.0% on the European capital market. LANXESS will use the funds to finance the planned acquisition of the Microbial Control business from U.S. corporation International Flavors & Fragrances Inc.
Net Financial Liabilities
| € million | Dec. 31, 2020 |
Sep. 30, 2021 |
|---|---|---|
| Non-current financial liabilities | 2,265 | 2,684 |
| Current financial liabilities | 566 | 188 |
| Less: | ||
| Liabilities for accrued interest | (25) | (29) |
| Cash and cash equivalents | (271) | (274) |
| Near-cash assets | (1,523) | (226) |
| Net financial liabilities | 1,012 | 2,343 |
Provisions for pensions and other post-employment benefits totaled €903 million as of September 30, 2021, compared with €1,205 million as of December 31, 2020. This decrease was chiefly due to an increase in the interest rates used to discount provisions for pensions and good asset performance.
OUTLOOK
The economic environment has continued to improve over the course of the year thanks to growing demand from major end user industries. However, the current development of energy prices in Europe is a negative factor. In addition, the effects of the coronavirus pandemic, especially bottlenecks in deliveries from China and the currently difficult global logistics situation, are an uncertainty factor for the global economy and for our businesses.
In some cases significant cost increases for logistics as well as interruptions to production as a result of power rationing in China are leading to further negative effects. Restrictions on production at German sites attributable to lower waste management capacity as a result of the incident at Currenta in Leverkusen-Bürrig must also be taken into account.
Against this background, we are specifying our forecast for fiscal year 2021 and expect EBITDA pre exceptionals to be at the lower end of the range of €1,000 million to €1,050 million.
FINANCIAL DATA AS OF SEPTEMBER 30, 2021
STATEMENT OF FINANCIAL POSITION LANXESS GROUP
| € million | Dec. 31, 2020 | Sep. 30, 2021 |
|---|---|---|
| ASSETS | ||
| Intangible assets | 1,647 | 2,469 |
| Property, plant and equipment | 2,674 | 2,961 |
| Investments in other affiliated companies | 2 | 46 |
| Non-current derivative assets | 4 | 20 |
| Other non-current financial assets | 41 | 50 |
| Non-current income tax receivables | 81 | 81 |
| Deferred taxes | 326 | 274 |
| Other non-current assets | 48 | 50 |
| Non-current assets | 4,823 | 5,951 |
| Inventories | 1,070 | 1,505 |
| Trade receivables | 745 | 1,076 |
| Cash and cash equivalents | 271 | 274 |
| Near-cash assets | 1,523 | 226 |
| Current derivative assets | 19 | 16 |
| Other current financial assets | 65 | 219 |
| Current income tax receivables | 101 | 86 |
| Other current assets | 145 | 217 |
| Assets held for sale and discontinued operations | 118 | – |
| Current assets | 4,057 | 3,619 |
| Total assets | 8,880 | 9,570 |
| € million | Dec. 31, 2020 | Sep. 30, 2021 |
|---|---|---|
| EQUITY AND LIABILITIES | ||
| Capital stock and capital reserves | 1,317 | 1,317 |
| Other reserves1) | 1,359 | 2,382 |
| Net income | 885 | 238 |
| Other equity components | (560) | (341) |
| Equity attributable to non-controlling interests | (2) | 6 |
| Equity | 2,999 | 3,602 |
| Provisions for pensions and other post-employment benefits | 1,205 | 903 |
| Other non-current provisions | 349 | 363 |
| Non-current derivative liabilities | 1 | 3 |
| Other non-current financial liabilities | 2,265 | 2,684 |
| Non-current income tax liabilities | 75 | 77 |
| Other non-current liabilities | 51 | 48 |
| Deferred taxes | 113 | 244 |
| Non-current liabilities | 4,059 | 4,322 |
| Other current provisions | 332 | 422 |
| Trade payables | 681 | 824 |
| Current derivative liabilities | 15 | 19 |
| Other current financial liabilities | 566 | 188 |
| Current income tax liabilities | 24 | 31 |
| Other current liabilities | 129 | 161 |
| Liabilities directly related to assets held for sale and discontinued operations | 75 | 1 |
| Current liabilities | 1,822 | 1,646 |
| Total equity and liabilities | 8,880 | 9,570 |
1) Also includes the reserve for own shares
INCOME STATEMENT LANXESS GROUP
| € million | Q3 2020 | Q3 2021 | 9M 2020 | 9M 2021 |
|---|---|---|---|---|
| Sales | 1,461 | 1,951 | 4,601 | 5,475 |
| Cost of sales | (1,111) | (1,469) | (3,422) | (4,091) |
| Gross profit | 350 | 482 | 1,179 | 1,384 |
| Selling expenses | (184) | (241) | (580) | (674) |
| Research and development expenses | (26) | (31) | (80) | (87) |
| General administration expenses | (57) | (70) | (195) | (213) |
| Other operating income | 12 | 13 | 55 | 45 |
| Other operating expenses | (42) | (49) | (161) | (128) |
| Operating result (EBIT) | 53 | 104 | 218 | 327 |
| Interest income | 2 | 1 | 7 | 5 |
| Interest expense | (13) | (15) | (48) | (47) |
| Other financial income and expense | (8) | 4 | 873 | 2 |
| Financial result | (19) | (10) | 832 | (40) |
| Income before income taxes | 34 | 94 | 1,050 | 287 |
| Income taxes | (9) | (26) | (159) | (79) |
| Income after income taxes from | ||||
| continuing operations | 25 | 68 | 891 | 208 |
| Income after income taxes from | ||||
| discontinued operations | 0 | 6 | (8) | 30 |
| Income after income taxes | 25 | 74 | 883 | 238 |
| of which attributable to non-controlling interests | (1) | 0 | (5) | 0 |
| of which attributable to LANXESS AG | ||||
| stockholders (net income) | 26 | 74 | 888 | 238 |
| Earnings per share (basic/diluted) (€) | ||||
| from continuing operations | 0.29 | 0.79 | 10.28 | 2.41 |
| from discontinued operations | 0.01 | 0.07 | (0.03) | 0.35 |
| from continuing and discontinued operations | 0.30 | 0.86 | 10.25 | 2.76 |
STATEMENT OF COMPREHENSIVE INCOME LANXESS GROUP
| € million | Q3 2020 | Q3 2021 | 9M 2020 | 9M 2021 |
|---|---|---|---|---|
| Income after income taxes | 25 | 74 | 883 | 238 |
| Items that will not be reclassified subsequently | ||||
| to profit or loss | ||||
| Remeasurements of the net defined benefit liability for | ||||
| post-employment benefit plans | (54) | 89 | (96) | 311 |
| Financial instruments fair value measurement | – | 22 | – | 27 |
| Income taxes | 16 | (29) | 21 | (94) |
| (38) | 82 | (75) | 244 | |
| Items that may be reclassified subsequently to | ||||
| profit or loss if specific conditions are met | ||||
| Exchange differences on translation of operations | ||||
| outside the eurozone | (127) | 92 | (170) | 215 |
| Financial instruments fair value measurement | 15 | (10) | 1 | (22) |
| Financial instruments cost of hedging | 0 | 1 | 0 | 0 |
| Income taxes | (5) | 3 | 0 | 6 |
| (117) | 86 | (169) | 199 | |
| Other comprehensive income, net of income tax | (155) | 168 | (244) | 443 |
| Total comprehensive income | (130) | 242 | 639 | 681 |
| of which attributable to non-controlling interests | (1) | 0 | 0 | 0 |
| of which attributable to LANXESS AG stockholders | (129) | 242 | 639 | 681 |
| Total comprehensive income attributable to | ||||
| LANXESS AG stockholders | (129) | 242 | 639 | 681 |
| from continuing operations | (130) | 231 | 625 | 642 |
| from discontinued operations | 1 | 11 | 14 | 39 |
STATEMENT OF CHANGES IN EQUITY LANXESS GROUP
| Capital | Capital | Other | Net income | Other equity components | Equity | Equity Equity |
||||
|---|---|---|---|---|---|---|---|---|---|---|
| stock | reserves | reserves | (loss) | Currency | Financial instruments | attributable to |
attributable to non |
|||
| € million | translation adjustment |
Fair value measurement |
Cost of hedging |
LANXESS AG stockholders |
controlling interests |
|||||
| Dec. 31, 2019 | 87 | 1,230 | 1,429 | 205 | (274) | (9) | 1 | 2,669 | (22) | 2,647 |
| Allocations to retained earnings | 205 | (205) | 0 | 0 | ||||||
| Acquisition of own shares | (37) | (37) | (37) | |||||||
| Dividend payments | (82) | (82) | – | (82) | ||||||
| Total comprehensive income | (75) | 888 | (175) | 1 | 0 | 639 | – | 639 | ||
| Income after income taxes | 888 | 888 | (5) | 883 | ||||||
| Other comprehensive income, net of income tax | (75) | (175) | 1 | 0 | (249) | 5 | (244) | |||
| Other changes | (2) | 2 | 0 | 0 | ||||||
| Sep. 30, 2020 | 87 | 1,230 | 1,438 | 888 | (449) | (6) | 1 | 3,189 | (22) | 3,167 |
| Dec. 31, 2020 | 87 | 1,230 | 1,359 | 885 | (569) | 9 | 0 | 3,001 | (2) | 2,999 |
| Allocations to retained earnings | 885 | (885) | 0 | 0 | ||||||
| Acquisition of own shares | (1) | 1 | – | – | 0 | |||||
| Dividend payments | (86) | (86) | (86) | |||||||
| Total comprehensive income | 224 | 238 | 215 | 4 | 0 | 681 | 0 | 681 | ||
| Income after income taxes | 238 | 238 | 0 | 238 | ||||||
| Other comprehensive income, net of income tax | 224 | 215 | 4 | 0 | 443 | 0 | 443 | |||
| Other changes | 0 | – | 0 | 8 | 8 | |||||
| Sep. 30, 2021 | 86 | 1,231 | 2,382 | 238 | (354) | 13 | 0 | 3,596 | 6 | 3,602 |
STATEMENT OF CASH FLOWS LANXESS GROUP
| € million | Q3 2020 | Q3 2021 | 9M 2020 | 9M 2021 |
|---|---|---|---|---|
| Income before income taxes | 34 | 94 | 1,050 | 287 |
| Amortization, depreciation, write-downs and | ||||
| reversals of impairment charges of intangible assets, | ||||
| property, plant and equipment | 117 | 133 | 369 | 372 |
| Gains on disposals of intangible assets and property, | ||||
| plant and equipment | 0 | 0 | (1) | 0 |
| Financial losses (gains) | 14 | 3 | (845) | 24 |
| Income taxes paid/refunded | (31) | 8 | (135) | (40) |
| Changes in inventories | 110 | (114) | 26 | (328) |
| Changes in trade receivables | (72) | (52) | (13) | (248) |
| Changes in trade payables | (11) | (34) | (111) | 65 |
| Changes in other assets and liabilities | 6 | 67 | (8) | (4) |
| Net cash provided by operating activities – | ||||
| continuing operations | 167 | 105 | 332 | 128 |
| Net cash (used in) provided by operating | ||||
| activities – discontinued operations | 1 | (10) | (16) | (26) |
| Net cash provided by operating activities – total | 168 | 95 | 316 | 102 |
| Cash outflows for purchases of intangible assets and | ||||
| property, plant and equipment | (102) | (109) | (264) | (271) |
| Cash inflows from sales of intangible assets and | ||||
| property, plant and equipment | 0 | 0 | 4 | 0 |
| Cash outflows for financial and other assets held for | ||||
| investment purposes | (102) | (100) | (1,443) | (253) |
| Cash inflows from financial and other assets held for | ||||
| investment purposes | 222 | 430 | 794 | 1,447 |
| Cash outflows for the acquisition/sale of subsidiaries | ||||
| and other businesses, less acquired cash and cash | ||||
| equivalents | – | (911) | (25) | (987) |
| Cash inflows from the sale of subsidiaries and other | ||||
| businesses, less acquired cash and cash equivalents | 6 | 33 | 818 | 113 |
| Interest and dividends received | 2 | 1 | 155 | 7 |
| € million | Q3 2020 | Q3 2021 | 9M 2020 | 9M 2021 |
|---|---|---|---|---|
| Cash outflows for external funding of pension | ||||
| obligations (CTAs) | (100) | – | (100) | – |
| Net cash (used in) provided by investing activities – continuing operations |
(74) | (656) | (61) | 56 |
| Net cash used in investing activities – discontinued operations |
(1) | 0 | (2) | (1) |
| Net cash (used in) provided by investing | ||||
| activities – total | (75) | (656) | (63) | 55 |
| Proceeds from borrowings | – | 505 | 1,000 | 510 |
| Repayments of borrowings | (9) | (516) | (1,036) | (541) |
| Interest paid and other financial disbursements | (6) | (2) | (51) | (42) |
| Dividend payments | (82) | 0 | (82) | (86) |
| Cash outflows for the acquisition of own shares | – | – | (37) | – |
| Net cash used in financing activities – | ||||
| continuing operations | (97) | (13) | (206) | (159) |
| Net cash used in financing activities – | ||||
| discontinued operations | (1) | 0 | (1) | 0 |
| Net cash used in financing activities – total | (98) | (13) | (207) | (159) |
| Change in cash and cash equivalents – | ||||
| continuing operations | (4) | (564) | 65 | 25 |
| Change in cash and cash equivalents – discontinued operations |
(1) | (10) | (19) | (27) |
| Change in cash and cash equivalents – total | (5) | (574) | 46 | (2) |
| Cash and cash equivalents at beginning of period – | ||||
| total | 340 | 847 | 296 | 271 |
| Exchange differences and other changes in cash and | ||||
| cash equivalents – total | (3) | 1 | (10) | 5 |
| Cash and cash equivalents at end of period – | ||||
| total | 332 | 274 | 332 | 274 |
| of which continuing operations | 332 | 274 | 332 | 274 |
| of which discontinued operations | 0 | – | 0 | – |
BUSINESS UNIT KEY DATA
Key Data by Segment/Third Quarter
| Advanced Intermediates | Specialty Additives | Consumer Protection | Engineering Materials | Reconciliation | LANXESS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| € million | Q3 2020 | Q3 2021 | Q3 2020 | Q3 2021 | Q3 2020 | Q3 2021 | Q3 2020 | Q3 2021 | Q3 2020 | Q3 2021 | Q3 2020 | Q3 2021 | |
| External sales | 414 | 533 | 466 | 605 | 278 | 353 | 285 | 436 | 18 | 24 | 1,461 | 1,951 | |
| Inter-segment sales | 10 | 9 | 2 | 2 | 11 | 9 | 0 | 0 | (23) | (20) | 0 | 0 | |
| Segment/Group sales | 424 | 542 | 468 | 607 | 289 | 362 | 285 | 436 | (5) | 4 | 1,461 | 1,951 | |
| Segment result/EBITDA | |||||||||||||
| pre exceptionals | 71 | 84 | 59 | 102 | 59 | 60 | 33 | 62 | (29) | (30) | 193 | 278 | |
| EBITDA margin pre exceptionals (%) | 17.1 | 15.8 | 12.7 | 16.9 | 21.2 | 17.0 | 11.6 | 14.2 | 13.2 | 14.2 | |||
| EBITDA | 71 | 84 | 54 | 98 | 59 | 54 | 32 | 62 | (46) | (61) | 170 | 237 | |
| EBIT pre exceptionals | 43 | 53 | 14 | 58 | 40 | 33 | 16 | 44 | (37) | (42) | 76 | 146 | |
| EBIT | 43 | 53 | 9 | 54 | 40 | 27 | 15 | 44 | (54) | (74) | 53 | 104 | |
| Segment capital expenditures | 28 | 34 | 30 | 43 | 16 | 22 | 20 | 13 | 13 | 19 | 107 | 131 | |
| Depreciation and amortization/ | |||||||||||||
| reversals of impairment charges | 28 | 31 | 45 | 44 | 19 | 27 | 17 | 18 | 8 | 13 | 117 | 133 | |
| Prior-year figures restated |
Key Data by Segment/First Nine Months
| Advanced Intermediates | Specialty Additives | Consumer Protection | Engineering Materials | Reconciliation | LANXESS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| € million | 9M 2020 | 9M 2021 | 9M 2020 | 9M 2021 | 9M 2020 | 9M 2021 | 9M 2020 | 9M 2021 | 9M 2020 | 9M 2021 | 9M 2020 | 9M 2021 | |
| External sales | 1,327 | 1,527 | 1,482 | 1,690 | 858 | 957 | 876 | 1,237 | 58 | 64 | 4,601 | 5,475 | |
| Inter-segment sales | 30 | 27 | 8 | 6 | 38 | 38 | 0 | 0 | (76) | (71) | 0 | 0 | |
| Segment/Group sales | 1,357 | 1,554 | 1,490 | 1,696 | 896 | 995 | 876 | 1,237 | (18) | (7) | 4,601 | 5,475 | |
| Segment result/EBITDA pre exceptionals |
256 | 257 | 210 | 265 | 194 | 194 | 110 | 189 | (108) | (108) | 662 | 797 | |
| EBITDA margin pre exceptionals (%) | 19.3 | 16.8 | 14.2 | 15.7 | 22.6 | 20.3 | 12.6 | 15.3 | 14.4 | 14.6 | |||
| EBITDA | 254 | 257 | 198 | 256 | 191 | 188 | 109 | 188 | (165) | (190) | 587 | 699 | |
| EBIT pre exceptionals | 171 | 165 | 77 | 139 | 134 | 129 | 60 | 136 | (130) | (141) | 312 | 428 | |
| EBIT | 169 | 165 | 65 | 129 | 113 | 123 | 59 | 135 | (188) | (225) | 218 | 327 | |
| Segment capital expenditures | 84 | 92 | 79 | 87 | 41 | 52 | 42 | 37 | 50 | 48 | 296 | 316 | |
| Depreciation and amortization/ reversals of impairment charges |
85 | 92 | 133 | 127 | 78 | 65 | 50 | 53 | 23 | 35 | 369 | 372 | |
| Employees as of Sep. 30 (previous year: as of Dec. 31) |
3,340 | 3,363 | 3,083 | 3,048 | 2,439 | 2,932 | 2,191 | 2,250 | 3,256 | 3,273 | 14,309 | 14,866 |
Prior-year figures restated
Financial Calendar 2021/2022
Contacts & Masthead
MASTHEAD
LANXESS AG Kennedyplatz 1 50569 Cologne, Germany Tel. +49 (0) 221 8885 0 www.lanxess.com
Agency: Kirchhoff Consult AG, Hamburg, Germany
English edition: EVS Translations GmbH, Offenbach, Germany
CONTACTS
Corporate Communications Christiane Minderjahn Tel. +49(0) 221 8885 2674 [email protected]
Investor Relations André Simon Tel. +49(0) 221 8885 3494 [email protected]
Date of publication: November 4, 2021
Disclaimer
This publication contains certain forward-looking statements, including assumptions, opinions and views of the company or cited from third-party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the company to differ materially from the estimations expressed or implied herein. The company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed herein or the actual occurrence of the forecasted developments. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither the company nor any of its parent or subsidiary undertakings nor any officers, directors or employees of such entities accepts any liability whatsoever arising directly or indirectly from the use of this document.
PUBLISHER
LANXESS AG
50569 Cologne
Germany